Citigroup raised its rating on Innate Pharma stock, which trades on the Nasdaq exchange. Leerink Partners also upgraded the rating. MarketBeat aggregates the rating data.
Steady: 0 in the last 7 days
Updated oct 14
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup raised its rating on Innate Pharma stock, which trades on the Nasdaq exchange. Leerink Partners also upgraded the rating. MarketBeat aggregates the rating data.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Leerink Partners assumed coverage on Equillium shares, with data reported by MarketBeat from Nasdaq listed stocks.Sub-event
Citigroup and Leerink Partners upgraded the rating for Innate Pharma stock.1 source
Keep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
-
Leerink partners
U.S. investment bank
-
Nasdaq
American fully electronic stock exchange
-
MarketBeat
American personal finance blog
Related events
- CleanSpark traded on the Nasdaq stock exchange, and Citigroup provided research reports and ratings.
- MarketBeat provided average rating data for the stock, and Citigroup began coverage on Whitehawk Therapeutics shares.
- MarketBeat provided stock average ratings while Leerink Partners upgraded and Barclays raised its price objective for Summit Therapeutics.
- MarketBeat aggregates consensus rating data on Aegon, while Citigroup weighed in and Morgan Stanley downgraded the rating.
- Jefferies, Citigroup, and Leerink Partners issued rating updates and price targets for Phathom Pharmaceuticals.